Clinical Trials Logo

Metastatic Tumors clinical trials

View clinical trials related to Metastatic Tumors.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02156388 Completed - Clinical trials for Chemotherapy-induced Neutropenia

Safety and Pharmacokinetic(PK) Study of GW003 to Metastatic Tumors

Start date: August 2013
Phase: Phase 1
Study type: Interventional

This study is designed to access the safety, tolerance and Pharmacokinetic/Pharmacodynamic(PK/PD) of single subcutaneous(SC) injection of GW003 in patients with metastatic tumors.

NCT ID: NCT01910545 Completed - Solid Tumors Clinical Trials

Phase 1 Study of OTS167 in Patients With Solid Tumors

Start date: August 23, 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety and tolerability of an investigational drug called OTS167. OTS167 is a maternal embryonic leucine zipper kinase (MELK) inhibitor which demonstrated antitumor properties in laboratory tests. It is being developed as an anti-cancer drug. In this first-in-human study OTS167 will be administered to patients with solid tumors which have not responded to treatment.

NCT ID: NCT00705497 Completed - Metastatic Tumors Clinical Trials

Radiofrequency Ablation of Tumors

Start date: January 2003
Phase: Phase 1
Study type: Interventional

Background: This prospective study was designed to be the first to evaluate the toxicity of radiofrequency ablation (RFA) in patients with recurrent pediatric solid tumors. Methods: From 2003 through 2006, we conducted a phase I, IRB-approved study of RFA for recurrent solid tumors. A multidisciplinary cancer management team selected appropriate candidates for the study. Imaging-guided RFA was performed percutaneously. Response was assessed at 3 months. Repeat RFA was performed for some incompletely ablated or new lesions.

NCT ID: NCT00676949 Completed - Metastatic Tumors Clinical Trials

Safety Study of Cancer Specific Epitope Peptides Cocktail for Cervical, GI, and Lung Tumors

peptidevac
Start date: November 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the clinical safety and efficacies of cyclophosphamide combined cancer specific epitope peptides cocktail for advanced/relapsed solid tumors including GI/lung/cervical cancers